Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 9/20 | 0.36 |
| ▸ | GSK3B | P49841 | 9/20 | 0.36 |
| ▸ | CDK1 | P06493 | 7/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20197285 | 0.88 | GSK3A (0.42) | ADORA3ADORA1ADORA2AGSK3AGSK3B | |
| SCHEMBL4370028 | 0.82 | ADORA1 (0.41) | ADORA3ADORA1ADORA2ADDAH1GSK3A | |
| SCHEMBL4371769 | 0.81 | GAA (0.41) | ADORA3ADORA1ADORA2ADDAH1GSK3A | |
| SCHEMBL1080357 | 0.78 | CCNB2 (0.40) | GSK3AGSK3BCDK1CDK5CCNB2 | |
| SCHEMBL24422924 | 0.78 | ADORA3 (0.38) | ADORA3ADORA1ADORA2ADDAH1GSK3A | |
| SCHEMBL1058944 | 0.76 | CCNB2 (0.38) | ADORA3GSK3AGSK3BCDK1CDK5 | |
| SCHEMBL15925247 | 0.74 | DAO (0.39) | AURKAAURKBPDE3BPDE3A | |
| SCHEMBL4295424 | 0.73 | NOS2 (0.58) | GSK3AGSK3BCDK1CDK5CDK2 | |
| SCHEMBL4370037 | 0.72 | NOS2 (0.41) | GSK3AGSK3BCDK1CDK5MAPK8 | |
| SCHEMBL32671116 | 0.72 | MAPK14 (0.35) | GSK3AGSK3BCDK1CDK5CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691814-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-1474425-B9 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1707566-A1 | Deazapurines and uses thereof | Eisai Co., Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1474425-B1 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050124649-A1 | Deazapurines and uses thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| WO-2004063336-A2 | USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS | EISAI CO. LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | ADORA3 54/4885ADORA1 50/4885ADORA2A 18/4885 |
| US-20050124649-A1 | Deazapurines and uses thereof | TPMT, CD38, CD2 | ADORA3 55/4885ADORA1 51/4885ADORA2A 18/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | ADORA3 455/4885ADORA1 508/4885ADORA2A 125/4885 |
| US-20040186127-A1 | Novel deazapurines and uses thereof | TPMT, ENTPD5, MTAP | ADORA3 30/4885ADORA1 36/4885ADORA2A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.